'Oncology Repurposing Engine' uses artificial intelligence to identify potential drug candidates among generics and off-patent drugs that may be repurposed as cancer therapies.
Janssen aims to expand the label of delivery in the US and EU for its product, Darzalex, to include subcutaneous delivery through the use of Halozyme’s technology.
Following Gilead’s funding of Lyndra’s technology, the latter company offers exclusive rights to its therapeutics platform for long-acting HIV therapies formulations.
EMA assembles pharmaceutical developers to strengthen antimicrobial pipelines while, in the meantime, a study found the world’s rivers dangerously contaminated.
Scancell and Cancer Research UK use nanodelivery technology to activate the body’s immune system, boosting its ability to target and destroy cancer cells.
Enesi Pharma and OVG sign a collaborative agreement, hoping to combine a promising ingredient and an innovative delivery method to produce a plague vaccine.
